Gene therapy | |
---|---|
Target gene | VEGF |
Vector | Plasmid |
Clinical data | |
Trade names | Neovasculgen |
Other names | Pl-VEGF165 |
Routes of administration | Intraneural injection |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). [1] [2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. [3] [4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.
Gene therapy | |
---|---|
Target gene | VEGF |
Vector | Plasmid |
Clinical data | |
Trade names | Neovasculgen |
Other names | Pl-VEGF165 |
Routes of administration | Intraneural injection |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). [1] [2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. [3] [4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.